---
layout: page
title: >-
  IBD Stock Of The Day Surges Higher On 4-Day Sprint For Medical Stocks
image: /assets/img/stock-of-the-day/2019-02-01.jpg
date: 2019-02-01 16:38 -0800
author: ALLISON GATLIN
---






Shares of [IBD Stock Of The Day](https://www.investors.com/research/ibd-stock-of-the-day/) **Medpace Holdings** ([MEDP](https://research.investors.com/quote.aspx?symbol=MEDP)) surged higher Friday amid a four-day buying spree for medical-research stocks. Medpace stock leads its industry group.




On the [stock market today](https://www.investors.com/market-trend/stock-market-today/stock-market-today-market-trends-best-stocks-buy-watch/), Medpace [stock](https://www.investors.com/research/stock-market-data-dow-jones-sp-500-nasdaq-spdr-etfs/) rose 2.1%, to 65.73. Shares popped as much as 3.8% to 66.83. Earlier this week, Medpace stock broke above a [buy point](https://www.investors.com/how-to-invest/investors-corner/chart-reading-basics-how-a-buy-point-marks-a-time-of-opportunity/) at 62.33 out of a [cup-with-handle](https://www.investors.com/how-to-invest/investors-corner/the-basics-how-to-analyze-a-stocks-cup-with-handle/) entry.


Medpace Helps Pharma, Biotech, Medtech
--------------------------------------


Medpace is a contract research organization. It helps [pharmaceutical, biotech and medical device firms](https://www.investors.com/news/technology/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead/) to perform the clinical studies necessary to grab approvals. Pharma companies can spend billions over decades in [drug development costs](https://www.investors.com/research/the-new-america/perkinelmer-drug-medical-research/).





IBD Newsletters
---------------


#### Get exclusive IBD analysis and actionable news daily.




SIGN UP NOW!





IBD Newsletters
---------------


#### Get exclusive IBD analysis and actionable news daily.




* Financial Advisor Update
* How To Invest
* Market Prep
* Tech Report



Please enter a valid email address
Please select a newsletter


GO
Get these newsletters delivered to your inbox & more info about our products & services. [Privacy Policy](https://www.investors.com/investors-business-daily-privacy-policy/) & [Terms of Use](https://www.investors.com/home/investors-business-daily-inc-terms-of-use/)



x



Thank You!
----------


#### You will now receive IBD Newsletters




ALL DONE!




Something Went Wrong!
---------------------


#### Please contact customer service




CLOSE




Some of those dollars go to [contract research organizations](https://www.investors.com/research/industry-snapshot/life-sciences-drug-development-biotech-big-pharma/) like Medpace and **PRA Health** ([PRAH](https://research.investors.com/quote.aspx?symbol=PRAH)). [Medpace's motto](https://www.medpace.com/) sums up the challenges of drug development: "We can't simplify clinical development — but we can execute it seamlessly."


The medical-research stock is specialized in an alphabet soup of [therapeutics](https://www.medpace.com/therapeutic-specialties/overview/). It has helped pharma companies working in everything from autoimmune diseases and cardiovascular to hematology/oncology and endocrine/metabolic disorders.


Sadif Investment Analytics says "Medpace Holdings has a bright prospect."


"It has little information risk or small market risk," Sadif said in a December note to clients. "The current sentiment in relation to Medpace is bullish with a neutral outlook. The company's business forecast is positive despite a deteriorating trend in our estimates."



Medpace Stock Has High Ratings
------------------------------


Sadif also notes Medpace's "high quality financials." Medpace's adjusted earnings per share have grown by double digits for the past four quarters. Revenue is on a similar path and has spiked by more than 50% each of the past three periods.


Medpace stock has been on a run this year, popping nearly 22% in January alone. At the same time, the broader universe of medical-research stocks has climbed about 10%. The group itself is ranked No. 83 out of 197 groups Investor's Business Daily tracks.


Shares of Medpace also rank first within that industry group. Medpace stock has a bullish [Composite Rating](https://www.investors.com/ibd-data-stories/companies-now-outperforming-95-of-all-stocks/) of 98 out of a best-possible 99, meaning its key growth metrics stand in the top 2% of all stocks.


Further, the medical-research stock has a [Relative Strength Rating](https://www.investors.com/research/best-stocks-rising-relative-strength/) of 97. The RS Rating pits a stock's 12-month performance against all other stocks. Medpace stock ranks in the top 3% of all stocks. It's also listed on the [IBD 50 list of elite growth stocks](https://research.investors.com/stock-lists/ibd-50/).


**YOU MIGHT ALSO LIKE:**


[Want More IBD Videos? Subscribe To Our YouTube Channel!](https://www.youtube.com/investorsbusinessdaily)


[Speedy Medtech: Why These Fast-Growing Stocks Should Be On Your Radar](https://www.investors.com/news/technology/fastest-growing-stocks-medical-technology-stocks/)


[How To Trade: Should You Buy A Stock Ahead Of Its Earnings Report?](https://www.investors.com/how-to-invest/investors-corner/should-you-buy-stock-ahead-of-earnings/)


[Which Pharmaceutical Stocks Are Outperforming All Other Stocks?](https://www.investors.com/news/technology/best-pharmaceutical-stocks-to-buy/)




